FDA approves expanded indication for Zomacton in adults with growth hormone deficiency.- Ferring Pharmaceuticals.
Ferring Pharmaceuticals announced that the FDA has approved an expanded indication for Zomacton (somatropin) for Injection 5 mg and 10 mg recombinant human growth hormone (GH) and it is indicated for replacement of GH in adults with GH deficiency. In 2015, the FDA granted approval for Zomacton to be marketed in the U.S. for treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone. Ferring developed and has marketed Zomacton outside of the U.S. since 1988 and in 47 countries globally.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins